Noxopharm Ltd
ASX:NOX
Legen Sie fest, zu welchem Kurs Sie kaufen würden. Wir helfen Ihnen, bereit zu bleiben.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Noxopharm Ltd
Nettogewinn
Noxopharm Ltd
Nettogewinn Peer-Vergleich
Noxopharm Ltd
Kurzansicht
Noxopharm Ltd. engages in the research and development of drugs. The company is headquartered in Gordon, New South Wales. The company went IPO on 2016-08-09. The firm is focused on the treatment of cancer and cytokine release syndrome or septic shock. The firm is engaged in the drug development program, which focuses on the treatment of pancreatic cancer and glioblastoma. The firm's lead drug candidate is called Veyonda (NOX66), which is a therapy developed for chemotherapy and radiotherapy in the treatment of late-stage cancers. Its drug candidate is in Phase II clinical trials. The firm's four pillar oncology program include externally delivered radiation (DARRT) Internally delivered radiation (LuPIN), Checkpoint inhibitors (IONIC) and Chemotherapy (CEP).
Auch interessant
Wie hoch ist Nettogewinn von Noxopharm Ltd?
Nettogewinn
-5.5m
AUD
Laut Finanzbericht vom Dec 31, 2025 beträgt Nettogewinn von Noxopharm Ltd -5.5m AUD.
Wie hoch ist die Wachstumsrate von Nettogewinn bei Noxopharm Ltd?
Nettogewinn CAGR 5J
-162%
Im letzten Jahr lag das Wachstum von Nettogewinn bei -137%. Die durchschnittlichen jährlichen Wachstumsraten von Nettogewinn bei Noxopharm Ltd lagen bei 29% über die letzten drei Jahre , -162% über die letzten fünf Jahre .
